Eloxx Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Eloxx Pharmaceuticals is Sumit Aggarwal, benoemd in Apr2021, heeft een ambtstermijn van 3.58 jaar. bezit rechtstreeks 5.15% van de aandelen van het bedrijf, ter waarde $ 0.15. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 6.5 jaar.

Belangrijke informatie

Sumit Aggarwal

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.6yrs
Eigendom CEO	5.1%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	6.5yrs

Recente managementupdates

Recent updates

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

Analyse CEO-vergoeding

Hoe is Sumit Aggarwal's beloning veranderd ten opzichte van Eloxx Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$24m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$575k	-US$36m
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$70m
Dec 31 2021	US$6m	US$408k	-US$67m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Sumit redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Sumit is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sumit Aggarwal (51 yo)

3.6yrs

Tenure

US$1,395,942

Compensatie

Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sumit Aggarwal	President	3.6yrs	US$1.40m	5.15% $ 0.2
Daniel Geffken	Interim CFO	3.6yrs	US$63.96k	0.038% $ 0.001
Barbara Ryan	Investor Relations Officer	no data	geen gegevens	geen gegevens
Ali Hariri	Chief Medical Officer	3yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ELOX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sumit Aggarwal	President	3.6yrs	US$1.40m	5.15% $ 0.2
Steven Rubin	Independent Director	6.9yrs	US$58.60k	0.36% $ 0.01
Alan Walts	Independent Director	3.6yrs	US$61.10k	0.39% $ 0.01
Patrick Flume	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Timor Baasov	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Noreen Henig	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
David Bedwell	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
Rachel Green	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
Sudhir Kumar	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
Lynne Maquat	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
Donald Vandevanter	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Christiane De Boeck	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

6.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ELOX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).

Eloxx Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

President exercised options and sold US$59k worth of stock

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

New minor risk - Shareholder dilution

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

New major risk - Market cap size

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Price target increased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Price target decreased to US$2.25

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Price target decreased to US$3.00

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President exercised options and sold US$59k worth of stock

Price target increased to US$4.03

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Eloxx Pharmaceuticals EPS misses by $0.06

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

CEO & Director exercised options and sold US$61k worth of stock

New 90-day high: US$4.51

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

New 90-day high: US$3.94

New 90-day low: US$2.42

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.68

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd